2021-10-20 16:00

Report from Extraordinary General Meeting of Vitrolife AB (publ)

At Vitrolife’s Extraordinary General Meeting today, the following, amongst other things, was decided:

  • Non-cash consideration issue in accordance with the board’s proposal with the purpose of financing the acquisition of Igenomix.
  • Vesa Koskinen, partner at EQT, is elected new board member and the board is thus expanded with one member. The board remuneration is increased because of the additional member. The decision is conditional on the non-cash issue being carried out.

Gothenburg, October 20, 2021
VITROLIFE AB (publ)
The Board

Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14

The information was submitted for publication, through the agency of the contact person set out above, at 4.00 pm CET on October 20, 2021.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

Related links